Bacillary angiomatosis is also known as epithelioid angiomatosis is an uncommon disease and is a disorder characterized by neovascular proliferation in the skin or the internal organs and presenting as tumor-like masses due to infection with Bartonella henselae or Bartonella quintana. Originally, bacillary angiomatosis was described in HIV patients but is known to occur in other non-HIV immunocompromised states as well as in immunocompetent persons. The neovascular proliferative lesions in the internal organs are known as peliosis and are common in liver and spleen. BA was first described in 1983 as an atypical subcutaneous infection associated with AIDS (Acquired immunodeficiency syndrome).
Bacillary angiomatosis is caused by two species of Bartonella genus namely Bartonella henselae and Bartonella quintana. The clinical spectrum of bacillary angiomatosis caused by these species differs. While both species cause cutaneous lesions, subcutaneous and osseous lesions are more frequent with B. quintana, and Bartonella henselae causes peliosis of the liver and spleen.
B. henselae is an aerobic, oxidase-negative, fastidious gram-negative rod, which is slightly curved. The temperature for optimal growth is 37 C. Under the microscope, the colonies appear like cauliflower. On average, B. henselae measure about 2 microns in length. B. henselae has a circular genome with a size of 1.9 Mbp, which is slightly larger than the genome of B. quintana (1.5 Mbp).
B. quintana is a Gram-negative bacterium which is slow-growing, and the morphology resembles short rods. It measures about 0.4 mm wide and 1.5 mm long.
Primary isolations of B. quintana may take 12-to 14 days and sometimes as long as 45 days. Both B. henselae and B. quintana do not have flagella as opposed to other related bacteria such as Bartonella bacilliformis. A twitching motion occurs due to fimbriae in both B. henselae and B. quintana.
There is very little published information regarding the epidemiology of the bacillary angiomatosis. Bacillary angiomatosis was first identified in patients who were infected with HIV and had low CD4 counts. During the pre-HAART era, the incidence of bacillary angiomatosis was 1.2/1000 patients. The most frequent site of involvement is the skin followed by bones and liver. Bacillary angiomatosis is rare amongst HIV patients due to antiretroviral therapy(ART). Bacillary angiomatosis in HIV patients can occur in the setting of non-compliance with ART or late diagnosis of HIV infection. A search in PubMed using terms bacillary angiomatosis and HIV results in 17 items after 2000. A careful analysis of these publications shows that five cases had low CD4 counts (less than 100), one case had CD4 over 500, one case was nonadherent to the ART regimen, in one case there was worsening of the bacillary angiomatosis in immune reconstitution phase, one case was on second-line regime based on lopinavir/ritonavir (Alluvia) and in one patient, bacillary angiomatosis was the presenting feature of AIDS. Thus, while bacillary angiomatosis is rare in the post-ART era, it can occur at any point in the natural history of the disease.
Bacillary angiomatosis can occur in non-HIV patients such as transplant patients, who have chronic hepatitis B, patients with leukemia, and those on chemotherapy particularly when the CD4 T-helper cell counts are suppressed. Bacillary angiomatosis in immunocompetent patients may occur at burn site, or site of cat scratch masquerading as a pyogenic granuloma. Therefore, bacillary angiomatosis must be in the differential diagnosis regardless of the immune status of the patient.
The most common organ is the skin. Although most cutaneous bacillary angiomatosis is treatable, the involvement of the internal organs can lead to fatal disease in some. There are two types of B. henselae. Type 1 causes peliosis, and type 2 is more likely to cause skin and lymph nodes lesions. Peliosis lesions are not seen in the lymph nodes.
The incidence of bacillary angiomatosis in the United States is not known, but bacillary angiomatosis has been reported in all states. States with a higher HIV population such as California, New York, and Florida have reported more cases. When compared to North America, fewer cases are reported from Europe. Bacillary angiomatosis has also been reported from Africa, Southeast Asia, Middle East, Australia, and South America. In the United States, about 40% of cases are Caucasians, 40% are blacks, and 20% are Hispanics. Ninety percent of cases of bacillary angiomatosis have been men. Bacillary angiomatosis is extremely rare in the pediatric age group, but cases have been reported from infancy to old age. Therefore, there is no age predilection.
About half of patients with BA are infected with B. henselae, and the remaining half of the infections are caused by B. quintana. It occurs equally in males and females.
In nature, cats are the reservoir of B. henselae. Cats may have episodes of asymptomatic bacteremia where the bacteria have adapted to life within the erythrocytes. The infection is acquired by cats via cat fleas (Ctenocephalides felis) when they carry B henselae or B quintana. Transmission of the organisms to humans by cats occur when they scratch humans. The body louse Pediculus humanus transmits B. quintana to humans.
Transmission to humans via cat fleas has been hypothesized but not documented. Transmission to humans via ticks has been reported. B. henselae has been isolated from both cat scratch disease and lesions in bacillary angiomatosis.
Humans were considered the only reservoir for B. quintana. However, Japanese macaques (Macaca fuscata) have recently been found to be another reservoir of B. quintana. B. quintana has been implicated in BA but has never been associated with cat scratch disease. Body louse transmits B. quintana in homeless, low socioeconomic and impoverished populations.
Once Bartonella species are inoculated by blood-sucking arthropods or penetrate the skin after exposure to cat, the gram-negative bacteria attach themselves to a variety of host cells, which include erythrocytes, monocytes, macrophages, and dendritic cells. The endothelial cell is an important target for B. quintana but not so much for B. henselae.
There are several mechanisms employed by Bartonella species to enter the host cells and are the result of complex interactions at the cell surface between the bacterial and host cell proteins. Therefore, Bartonella species are highly host-specific. First, adhesion of the bacteria to the host cell membrane is followed by uptake of groups of Bartonella in a vacuole by the host cell. In a second mechanism, bacteria accumulate on the host cell surface and induce self-phagocytosis. This process results in phagosome where Bartonella species must survive the harsh environment resisting enzymes of oxidative stress. Both are well-equipped to deal with intracellular oxidative stress and produce heat shock proteins. A third mechanism is specific for entry into the erythrocytes, which involves secretion of a protein called deformin. Deformin causes, invaginations of the erythrocyte membrane providing entry points for these bacteria which are adept at rearranging the cell cytoskeleton once they are attached to the cell surface. These bacteria are the carpenters of the bacterial world.
Bartonella is the only genus known to release factors that stimulate endothelial cells to produce angiopoietin-2 and epidermal production of vascular endothelial growth factor. BadA protein on the cell surface of B. henselae is responsible for adhesion to endothelial cells and fibronectin. BadA protein is responsible for promoting angiogenesis in B. henselae infections. BadA protein is also known to promote angiogenesis via inducible hypoxia factor-1 (IHF-1). Expression of outer membrane proteins (Vomp) is responsible for promoting vascular growth in the case of B. quintana.
The ability to enter the erythrocytes protects these species from the host’s adaptive and innate immune response. The CD4 T-helper cells produce interferon gamma and TNF alpha, which are responsible for eliminating the bacteria. The Bartonella species are capable of attenuating the host immune response thereby establishing a chronic asymptomatic carrier state. An asymptomatic carrier state caused by B. quintana exemplifies this in homeless patients.
The most common clinical presentation is a papule that develops into a reddish to a purple nodule, which appears vascular. The nodules can be small as a pinhead to as large as 10 cm in diameter. As a nodule enlarges, there is central ulceration and bleeding from this nodule. The usual site is the upper extremities. A patient may have multiple papules and nodules as the lesions often arise in crops. The differential diagnosis of a nodule is extensive however confusion is most likely to occur with Kaposi’s sarcoma (KS) in HIV patients, pyogenic granuloma (PG) in immunocompetent patients. The histology of bacillary angiomatosis is identical to that of pyogenic granuloma, therefore cannot be differentiated based on pathology alone. Multiple lymph nodes along the arm may resemble sporotrichosis. Lymphadenopathy is infrequent in bacillary angiomatosis.
While most patients have an immunosuppressed state, rarely a nodule in an otherwise healthy person may be due to bacillary angiomatosis. Therefore, BA should be in the differential diagnosis of any nodule of unknown etiology. There is no diagnostic feature on gross morphology that suggests cutaneous BA hence a high index of suspicion is required.
Similar lesions occur in the oral mucosa, tongue, oropharynx, nose, penis, and anus. The pathogenesis of these lesions is not defined. The lesions in the gastrointestinal mucosa can cause bleeding. Neuropsychiatric symptoms, endocarditis and weight loss, abdomen pain, are other symptoms of visceral bacillary angiomatosis. Neurological involvement is very rare and has been reported in a case report which showed intracerebral bacillary angiomatosis which preceded the development of the cutaneous lesions.
Bacillary angiomatosis can also be an invasive disease. B. henselae or B. quintana can invade and set-up infection in the heart, brain, liver, spleen, larynx, lymph nodes and gastrointestinal tract. There does not have to be a history of exposure to cats. When there are no associated cutaneous lesions, the diagnosis of invasive bacillary angiomatosis is likely to be delayed. The features associated with hepatic and splenic bacillary peliosis are nonspecific such as fever, lymphadenopathy, visceromegaly, anemia and elevated alkaline phosphatase. Often bacillary angiomatosis can present as fever of unknown origin (FUO). While most frequently hepatic and splenic peliosis lesions are asymptomatic, there are reports of spontaneous hemorrhage and hemoperitoneum at presentation. Patients may also report other symptoms of systemic involvement such as fever, chills, weight loss and anorexia.
In patients who are not severely immunosuppressed, there may be inflammatory nodules involving the internal organs without angiomatosis. This appears to be on a spectrum of infections caused by B. henselae and intermediate between bacillary angiomatosis and cat scratch disease.
B. quintana infections can cause cutaneous bacillary angiomatosis as well involvement of the subcutaneous tissues, and bone but do not cause peliosis in the liver and spleen.
When a cutaneous nodule is present, a biopsy is ideal to diagnose bacillary angiomatosis. Work up to exclude peliosis of the liver and spleen should be done. Further evaluation can be done based on the associated symptoms and physical exam. Some prominent differential diagnoses to consider are KS, PG, and benign hemangioma. In endemic regions, the lesions may be confused with verruga peruana due to B. bacilliformis. Histological evaluation is used to differentiate bacillary angiomatosis from neovascular tumors.
In routine clinical practice, histological methods are used to confirm the diagnose bacillary angiomatosis. The hematoxylin and eosin (H and E) stain demonstrate endothelial-lined peliosis spaces. Warthin-Starry stain shows clumps of bacteria. The histological methods cannot make a diagnosis to the species level.
Serology at the initial presentation followed by a fourfold rise during convalescence is useful and more sensitive than culture methods. Immunofluorescence assays (IFA) detecting immunoglobulin G (IgG) and immune enzyme assays (EIA) have been developed. The reported sensitivity of serological tests developed by the Centers for Disease Control and Prevention (CDC) is reported to be between 85% to 94%. However, there is cross-reactivity between B. henselae and B. quintana as well as Coxiella and Chlamydia species.
PCR (polymerase chase reaction) based testing performed on whole blood, serum samples or plasma can identify and differentiate between the different species of Bartonella.
Culture methods are insensitive. In patients with endocarditis, the sensitivity of shell vial culture was 28% in one study. The sensitivity of culture on agar plates was only 5% in the same study. Therefore, culture methods are not employed in clinical practice.
The drug of choice is macrolide erythromycin or doxycycline. In patients who are not able to tolerate erythromycin or doxycycline, azithromycin or clarithromycin may be used. Mild cutaneous BA can be treated for 12 weeks. The response is seen by three to four weeks. The nodule size and the number may be followed to determine the response to therapy. If the response is not satisfactory, the duration of therapy can be extended. Antibiotic therapy can cure most cutaneous lesions. Even peliosis responds to antibiotic therapy. The duration of therapy has not been determined and most likely longer in cases with invasive disease. Infectious disease consultations should be obtained. In patients who are immunosuppressed, therapy should be continued till the CD4 T-helper cell count normalizes. In HIV patients, antiretroviral therapy is essential however a case of immune reconstitution inflammatory syndrome has been reported. Therapy in HIV patients should be continued until the CD4 count remains above 200 cells/microliter for over six months.
Cryotherapy, electrodesiccation with curettage, and surgical excision of solitary cutaneous lesions can be useful as adjunctive therapy after treatment with antibiotics to prevent occult bacteremia during the procedure.
In vitro susceptibility does not correlate with clinical response. Bactrim, Beta-lactams, and fluoroquinolones do not interfere with the recovery of the organisms in culture. Tetracyclines, macrolides, and rifampin dramatically reduce the recovery of the organisms in cultures.
Since the cat carries the bacillus only for a short period of time, disposal of the cat is not routinely recommended. Declawing of the cat makes no difference in the transmission rates from cats to humans. Strict Flea-control measures are recommended and should be performed on a regular basis and is the only effective preventive measure.
Clinically, the physical appearance of the cutaneous lesions may be indistinguishable from those of Kaposi sarcoma, pyogenic granuloma, and epitheliod hemangioma. In endemic regions, the lesions may be confused with verruga peruana due to B. bacilliformis. Multiple lymph nodes along the arm may also resemble sporotrichosis.
Bacillary angiomatosis resolves rapidly when antimicrobial therapy is instituted early. Relapses are common in immunocompromised patients and can occur after cessation of therapy. However, if the infection is not treated appropriately it can be fatal.
Infectious disease consultations should be obtained. Sometimes a surgical consultation may be required for adjunctive procedures like cryotherapy, electrodesiccation with curettage, and surgical excision of solitary cutaneous lesions.
Bacillary angiomatosis resolves rapidly when antimicrobial therapy is instituted early. However, if the infection is not treated appropriately it can be fatal. Strict Flea-control measures are the only effective preventive measure.
In solid organ transplant (SOT) patients, a combination of macrolide and doxycycline has been used. However, doxycycline may be preferred drug in this patient due to increased drug-drug interactions with macrolides.
Management of bacillary angiomatosis requires an interprofessional effort from primary care physicians and infectious disease team. Lesions should be identified early, and treatment should be started early in the disease course to prevent any complications. Regular monitoring of CD 4 counts in HIV patients is recommended. Nurses should educate patients on the measures to be taken at home for prevention of infections in immunocompromised patients like prevention of cat scratches and controlling flea infestations. Pharmacists should be aware of the potential complications of drugs used in the treatment of bacillary angiomatosis.
|||Stoler MH,Bonfiglio TA,Steigbigel RT,Pereira M, An atypical subcutaneous infection associated with acquired immune deficiency syndrome. American journal of clinical pathology. 1983 Nov; [PubMed PMID: 6637883]|
|||Diddi K,Chaudhry R,Sharma N,Dhawan B, Strategy for identification & characterization of Bartonella henselae with conventional & molecular methods. The Indian journal of medical research. 2013 Feb [PubMed PMID: 23563383]|
|||Foucault C,Brouqui P,Raoult D, Bartonella quintana characteristics and clinical management. Emerging infectious diseases. 2006 Feb [PubMed PMID: 16494745]|
|||Diniz LM,Medeiros KB,Landeiro LG,Lucas EA, Bacillary angiomatosis with bone invasion. Anais brasileiros de dermatologia. 2016 Nov-Dec [PubMed PMID: 28099606]|
|||Madua MC, Bacillary angiomatosis: A rare finding in the setting of antiretroviral drugs. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 2015 Oct [PubMed PMID: 26636153]|
|||Nikam BP,Vijayendran N,Jamale V,Kale M, Bacillary Angiomatosis in an Immunocompetent Individual. Indian dermatology online journal. 2018 May-Jun [PubMed PMID: 29854648]|
|||Cotté V,Bonnet S,Le Rhun D,Le Naour E,Chauvin A,Boulouis HJ,Lecuelle B,Lilin T,Vayssier-Taussat M, Transmission of Bartonella henselae by Ixodes ricinus. Emerging infectious diseases. 2008 Jul [PubMed PMID: 18598628]|
|||[PubMed PMID: 27375211]|
|||[PubMed PMID: 27258788]|
|||[PubMed PMID: 27752473]|
|||[PubMed PMID: 8703269]|
|||[PubMed PMID: 27428207]|
|||[PubMed PMID: 1558347]|
|||[PubMed PMID: 2399342]|
|||[PubMed PMID: 12853405]|
|||[PubMed PMID: 12624031]|
|||[PubMed PMID: 2378904]|
|||[PubMed PMID: 27051835]|
|||[PubMed PMID: 28393665]|
|||[PubMed PMID: 23813816]|
|||[PubMed PMID: 7551113]|
|||[PubMed PMID: 12894361]|